INTRODUCTION
The Philadelphia chromosome (Ph) is the der (22) of the reciprocal translocation t(9;22)(q34;q11), which encodes the BCR/ABL, the oncogenic driver of chronic myeloid leukemia (CML) and 20-25% of cases of adult acute lymphatic leukemia (ALL). Tyrosine kinase inhibitors (TKI), designed to abrogate the oncogenic function of BCR/ABL, have greatly improved the overall prognosis of these diseases, particularly by altering the natural history of chronic phase (CP) CML and preventing the previously inexorable progression to terminal blast crisis (BC). 1 Most patients with CML-CP treated with imatinib are now anticipated to have a nearly normal life expectancy, 2 but its impact on outcome has been less decisive in patients with CML-BC 3 and outcome remains dismal in patients with CML-BC or Ph+ ALL. 4, 5 This is due to the high rate of primary and acquired resistance to imatinib in advanced disease stages, but resistance may be observed even in a small but clinically relevant subset of CML-CP patients. In the pivotal IRIS trial,~50% of patients displayed either primary resistance based on cytogenetic response at 18 months or secondary resistance after 5-year follow-ups. 6, 7 Point mutations in the tyrosine kinase domain (TKD) of BCR/ABL have emerged as the predominant cause of acquired resistance. They are observed in up to 80% of patients with CML-BC and Ph+ ALL [8] [9] [10] [11] [12] and~50% of imatinib-resistant CML patients overall. 13, 14 This led to the development and regulatory approval of second generation TKI (nilotinib, dasatinib and bosutinib) that are more potent inhibitors of native BCR/ABL and of most TKD mutants. Their clinical use as second-line and more recently first-line therapy for all phases of CML [15] [16] [17] [18] [19] [20] and Ph+ ALL has improved treatment options and outcome but has not abrogated the problem of resistance, particularly in advanced disease. Notably, the pattern of TKD mutations emerging with clinical resistance depends on the specific TKI administered, and reflects the relative potency of the individual TKIs toward different TKD mutations (for nilotinib: T315, Y253, E255 and F359 residues; dasatinib: T315, F317 and V299 residues). [21] [22] [23] The presence of mutations is associated with inferior survival in patients resistant to TKI highlighting the need for more effective therapy. 8, 12, 24, 25 In particular, the gatekeeper mutation T315I has emerged as the clinically most challenging TKD mutation due to its resistance to all approved second generation TKI.
Ponatinib is a potent inhibitor of native BCR/ABL and BCR/ABL-T315I that also inhibits all known BCR/ABL mutants in vitro, as well as in vivo 26 and was the first third-generation TKI to be approved for treatment of CML and Ph+ ALL after showing pronounced antileukemic activity in phase I and II studies of patients with multi-TKI-resistant disease or presence of the T315I mutation. 27, 28 As a multikinase inhibitor, ponatinib also targets kinases implicated in mutation-independent resistance to TKI, for example, SRC. On the other hand, the broad spectrum of kinases inhibited by ponatinib, including VEGF receptors, FGF receptors, PDGF receptors, EGF receptor, c-KIT, FLT3 and RET kinases, may enhance the potential for adverse effects, including pancreatitis or myelosuppression. 27 This concern has been exacerbated by recent clinical data indicating a high rate of cardiac and vascular adverse events during ponatinib treatment. The development of other compounds active against BCR/ABL-T315I, including several aurora kinase inhibitors, has likewise been hampered by issues of poor specificity and tolerability. [29] [30] [31] Clinical experience shows that in Ph+ ALL and CML-BC responses to all TKIs tested to date are limited and transient, 32, 33 despite administration of TKI considered appropriate based on the results of mutational analysis. 28 Thus, important therapeutic obstacles other than tolerability and appearance of resistance, TKD mutations are mutation-independent mechanisms of resistance that are caused by, as yet, insufficiently characterized cell intrinsic mechanisms. 34, 35 These include amplification of BCR/ABL, aberrant phosphatase activity, aberrant drug transporter activity and 'sanctuary sites' for example, the central nervous system. 36, 37 Taken together, these data highlight the unmet need of effective and safe agents available for treatment of patients with advanced and therapy-resistant Ph+ leukemias, and those harboring BCR/ABL-T315I in particular. Here we report the design and preclinical evaluation of a highly selective, orally available TKI, PF-114, which potently inhibits native BCR/ABL, as well as BCR/ ABL-T315I and other clinically relevant resistance mutations in biochemical, cellular and in vivo survival models. These data warrant consideration for single-agent clinical testing of PF-114 in patients resistant to available TKI and hold particular promise for controlling BCR/ABL-T315I-driven disease.
MATERIALS AND METHODS

Compounds, ponatinib and PF-114
PF-114 was synthesized as described in Supplementary Figure S1 . Ponatinib was purchased from Selleck Chemicals (Houston, TX, USA). The compounds were diluted in dimethyl sulfoxide to a stock solution 1000 × , then diluted to working concentrations. For the in vivo experiments, the compounds were diluted to working concentration in 0.5% methylcellulose (Methocel 65HG, Fluka/Sigma, Taufkirchen, Germany).
Kinase inhibition assay
Kinase inhibition was measured at Reaction Biology Corp. (San Diego, CA, USA), using its proprietary 'Kinase Hot Spot' assay. For IC 50 measurements of PF-114 and ponatinib on a selected set of kinases, 10 concentrations were tested in duplicates starting from 1 μM with threefold serial dilution. Staurosporine was used as a positive control. For kinase selectivity profiling PF-114, ponatinib, dasatinib and nilotinib were tested in a single concentration of 100 nM in duplicate against a panel of 337 kinases.
Molecular modeling
The initial coordinates of ABL WT (PDB ID: 3OXZ), 38 ABL T315I (PDB ID: 3IK3), 26 B-RAF (PDB ID: 3Q96) 39 and VEGFR2 (PDB ID: 3VHE) 40 kinases were obtained from the Protein Data Bank. Polar hydrogen atoms and missing protein residues were added using Build model program. 41 Binding poses of PF-114 and ponatinib were first hypothesized using Lead Finder docking software 42 and then refined according to the following molecular dynamics protocol. Models of protein-ligand complexes were solvated with water molecules using the genbox utility of the GROMACS 4.5 simulation package 43 (crystallographic water molecules were retained). Molecular mechanics parameterization of ligands was performed with ACPYPE. 44 OPLS-AA force field and TIP4P water model were used in further molecular dynamics simulations, which included energy minimization step, 100-ns NVT equilibration and 2-ns NPT production run.
Cell lines and patient-derived long-term cultures (PD-LTCs)
All cell lines were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). K562, KCL-22, SupB15, Tom-1, BV-173 and Jurkat cells were maintained in RPMI 1640 supplemented with 10% fetal calf serum (FCS; Gibco/Invitrogen, Karslruhe, Germany). The packaging cell line Phoenix was cultured in dimethyl sulfoxide with 10% FCS. Ba/F3 cells were grown in RPMI+10% FCS supplemented with 10 ng/ml mIL-3 (Cell Concepts, Umkirch, Germany). Ph + ALL PD-LTCs were maintained in a serum-free medium as described previously. 45 
FLT3-ITD, c-Kit-D814H, BCR/ABL and its mutants
The FLT3-ITD cDNA was kindly provided by Christian Brandts (Goethe University, Frankfurt, Germany). c-Kit-H814D, p185 BCR/ABL and its resistant mutants (Y253F, E255K and T315I) were reported previously. 46, 47 The p185-F317L BCR/ABL was created from p185 BCR/ABL and the p185-T315I-E255K BCR/ABL from p185-T315I BCR/ABL cDNA by using the QuikChange1 II Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's instructions. The following primers were used: forward-F317L 5′-GTTCTATATCATCACTGAGCTTATGACCTACGG GAACCTCC-3′; reverse-F317L 5′-GGAGGTTCCCGTAGGTCATAAGCTCAGTGA TGATATAGAAC-3′ and forward-E255K 5′-GGGGGCCAGTACGGGAAAGTGT ACGAGGGCG-3′; reverse-E255K 5′-CCCTCGTACACTTTCCCGTACTGGCCCC CGCC-3′. After sequencing the cDNAs of FLT3-ITD, p185 BCR/ABL and its mutants were cloned into the pENTR1A Gateway vector for further recombination into the retroviral PINCO Gateway-destination vectors. 48 
Western blotting
Western blotting was performed according to widely established protocols. The following antibodies were used: anti-ABL (α-ABL) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-ABL specific for the phosphorylated Y245 (α-p-ABL-Y245) (Upstate-Biotechnology, Lake Placid, NY, USA); anti-CRKL; and anti-phosphorylated CRKL (Cell Signaling, Boston, MA, USA), anti-STAT5; and anti-phosphorylated STAT5 (Cell Signaling). Blocking was performed in 5% low-fat dry milk (Roth, Karlsruhe, Germany).
Cytotoxicity/proliferation and apoptosis
Cytotoxicity/proliferation was assessed by using the XTT Proliferation Kit (Roche, Mannheim, Germany) according to the manufacturer's instructions. Cell growth was assessed by dye exclusion using Trypan-blue and apoptosis by 7-AAD staining as described before. 46 Isolation of Sca1 + hematopoietic stem and progenitor cells Sca1 + cells were isolated from the bone marrow (BM) of 8-to 12-week-old female C57BL/6N mice (Janvier St. Berthevin, France) using the Sca1 + Enrichment Kit according to the manufacturer's instructions (Miltenyi, Bergisch Gladbach, Germany).
Retroviral infection
Ecotropic Phoenix packaging cells were transfected with the PINCO vectors. 46 The retroviral supernatant was collected after 36 h. Sca1 + cells prestimulated for 2 days in Dulbecco's modified Eagle's medium, 10% FCS, mIL-3 (20 ng/ml), mIL-6 (20 ng/ml) and mSCF (100 ng/ml; Cell Concepts) or Ba/F3 cells were plated onto retronectin-coated (Takara-Shuzo, Shiga, Japan) nontissue culture 24-well plates and exposed to the retroviral supernatant for 3 h at 37°C.
Syngeneic transduction/transplantation model of CML C57BL/6N mice (8-12 weeks) were sublethally irradiated with 4.5 Gy. Retrovirally infected donor cells (10 5 ) were inoculated via tail vein. Mice were killed at the first appearance of morbidity (loss of weight 410%, neurological abnormalities and failure to thrive or diarrhea).
Syngeneic BCR/ABL-induced ALL
Cryopreserved BM cells (4 × 10 4 ) from C57BL/6N mice with BCR/ABL-driven ALL were injected via tail vein into sublethally irradiated recipient. Mice were killed at the first appearance of morbidity.
K562 xenograft in nude mice
K562 cells (5 × 10 6 ) were implanted subcutaneously into the right flank of female BALB/cAnNRj-Foxn1 nu mice (Charles River, Sulzfeld, Germany). Mice were randomized to treatment groups when the average tumor volume (tumor volume = L × W 2 × 0.5) reached about 500 mm 3 . Mean tumor volume was measured every 3 days. T315I-positive Ph+ ALL xenograft model BCR/ABL-T315I-positive PD-LTC (KÖ) cells (4 × 10 6 ) were inoculated via tail vein into sublethally irradiated (2.5 Gy) NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. These mice were bred at the animal facility of the Georg-Speyer Haus, Frankfurt, Germany, under specific pathogen-free conditions. Mice were killed at the first appearance of morbidity.
Retrovirus-based mutagenesis screen
For a modified retrovirus-based mutagenesis screen, 37 Ba/F3 cells were retrovirally transduced with either p185 BCR/ABL or its resistance mutants and selected by interleukin (IL)-3 withdrawal. A perfectly balanced pool of 10 7 cells was cultured with increasing concentrations of PF-114 (0, 50, 100 and 500 nM). After 28 days clones were obtained by limiting dilution in 96-well plates. Genomic DNA for sequencing the BCR ABL kinase domain was extracted using QIAamp DNA Mini Kit (Qiagen, Düsseldorf, Germany). For amplification the following primers were used: ALL-TB 5′-GCAAGACC GGGCAGATCT-3′ and R-ABL-A 5′-GTTGCACTCCCTCAGGTAGTC-3′. 10 PCR products were sequenced by Seqlab (Göttingen, Germany) using the AN4 5′-TGGTTCATCATCATTCAACGGTGG-3′. 49 The sequence data were analyzed for mutations with Clone Manager Professional (Sci ED Software, Morrison, NC, USA).
Statistical analysis
Student's t-tests or Mantel-Cox test for the determination of statistical significance of survival curves were performed using the GraphPad Prism (GraphPad Software, San Diego, CA, USA).
RESULTS
Design of PF-114 for interaction with ABL-T315I and improved kinase selectivity
For the design of an inhibitor with the same potency but a better selectivity profile two main structural hypotheses were considered: (i) to render repulsion with the main chain carbonyl oxygen, present in the ATP-binding site of many off-target kinases (for example, main chain carbonyl of residue E917 in VEGFR2; Supplementary Figure S2 , Supplementary Table S1 ), a partially negatively charged nitrogen atom was placed into corresponding position of the ponatinib scaffold ( Figure 1a ); (ii) to disrupt potential hydrogen bond between the water molecule present in the active site of some off-target kinases (for example, in B-RAF kinase active site, Supplementary Figure S1 and S2) and piridazine, nitrogen atom of ponatinib was replaced with a carbon atom The effect of PF-114 and ponatinib on the factor-independent growth of Ba/F3 expressing either FLT3-ITD or c-Kit-D814H was performed on cells selected by IL-3 withdrawal. These cells were exposed to increasing concentrations of PF-114 or ponatinib as indicated. Cell proliferation and viability was assessed by XTT assays.
( Figure 1a ). The favorable binding of PF-114 in the active site of ABL and its T315I-mutant was confirmed by molecular modeling (Figure 1b ; for ponatinib see Supplementary Figure S3 ).
The inhibitory effects of PF-114 on the ABL kinase and ABL harboring the clinically relevant mutations were confirmed in a cell-free kinase inhibition assays ( Table 1 ). The activity range of PF-114 was similar to that of ponatinib, 26, 50 whereas IC 50 s for nilotinib were higher. 51 Selectivity of PF-114 was investigated in direct comparison with ponatinib, dasatinib and nilotinib by the determination of the inhibition profile of 337 human kinases. We used a concentration of 100 nM, which corresponds to the clinically feasible plasma concentrations of ponatinib and dasatinib, respectively. 52 As a threshold, a minimum of 90% of inhibited kinase activity was selected. PF-114 potently inhibited 11 kinases, whereas ponatinib inhibited 47, dasatinib 36 and nilotinib 4 kinases, respectively (Figure 1c , Supplementary Table S2 ).
Extrapolating the kinase inhibition of nilotinib to its clinically relevant concentration of 4 μM the number of inhibited kinases reached 21 ( Supplementary Table S2 ). Like ponatinib and dasatinib, PF-114 potently inhibited ABL2, DDR1, DDR2, FMS, FRK, LCK, LYN and PDGFR kinases, whereas it did not inhibit c-SRC, CSK or c-KIT. Furthermore as compared with ponatinib it spared EPHRIN, FLT3, FGFR, VEGFR and B-RAF. To confirm differences between PF-114 and ponatinib regarding their target profile, we compared the effects of PF-114 and ponatinib on constitutively activated FLT3 and c-KIT in a cellular model. We used FLT3-ITD or c-Kit-D814H, the murine analogue of c-KIT-D816H and retrovirally expressed them in factor-dependent Ba/F3 cells. After selection by factor withdrawal the cells were exposed to increasing concentrations of PF-114 and ponatinib. Whereas PF-114 did not show any activity below a concentration of 500 nM, ponatinib inhibited both FLT3-ITD and c-Kit-D814H in a low nanomolar range (Figure 1d ).
Whether the different target profiles influence toxicity was investigated on primary Sca1 + /linmurine hematopoietic stem and progenitor cells in a colony assay in semisolid medium. Whereas PF-114 did not reduce the colony number even at 5 μM, ponatinib began to reduce colonies starting from 500 nM Figure S4) . For further preclinical toxicity data and pharmacokinetics of PF-114 see Supplementary information and  Supplementary Tables S3-S5) .
Taken together, these data show that PF-114 is a potent TKI with a more restricted selectivity profile as compared with ponatinib or dasatinib.
PF-114 inhibits the autophosphorylation of BCR/ABL and BCR/ ABL-T315I and abolishes factor-independent growth of Ba/F3 cells mediated by BCR/ABL and its resistance mutants The activity of a kinase inhibitor in a cell context can strongly differ from that in cell-free systems. Therefore we studied the effects of PF-114 on the autophosphorylation of BCR/ABL and BCR/ABL-T315I in Ba/F3 cells, as a read out of ABL kinase activity.
We retrovirally transduced Ba/F3 cells with either native BCR/ ABL or BCR/ABL-T315I and exposed them to increasing concentrations of PF-114. Ponatinib (100 nM) was used as a positive control. Autophosphorylation of BCR/ABL was addressed by an antibody directed against the phosphorylated Y245 residue in ABL. The IL-3-dependent Ba/F3 cells are factor independent upon expression of BCR/ABL. To avoid bias of stress-induced signaling by factor withdrawal, we performed these experiments in the presence of IL-3. PF-114 inhibited the autophosphorylation of BCR/ABL and BCR/ABL-T315I in a dose-dependent manner similar to ponatinib (Figure 2a ). PF-114 also inhibited substrate phosphorylation as shown by the reduced Crkl-phosphorylation and downstream activation of Stat5 by BCR/ABL, as well as by BCR/ ABL-T315I (Figure 2a ).
The effect of PF-114 on the factor-independent growth of Ba/F3 expressing BCR/ABL was performed on cells selected by IL-3 withdrawal. Cell proliferation and viability was assessed by XTT assays. As shown in Figure 2b , PF-114 potently inhibited proliferation of Ba/F3 cells expressing native BCR/ABL in a dosedependent manner with IC 50 of 5-10 nM. No effect was seen on empty vector-transduced Ba/F3 cells in the presence of IL-3 at concentrations at least until 2 μM (Figure 3b ).
Next we extended our investigations on the clinically most important resistance mutants of BCR/ABL like Y253F, E255K (imatinib resistance), F317L (dasatinib resistance) and T315I (global resistance). PF-114 effectively inhibited the growth of Ba/F3 cells expressing these mutants with an IC 50 of 25-100 nM. The BCR/ABL-F317L, responded starting from 100 nM of PF-114 ( Figure 2c ). Growth inhibition by both PF-114 and ponatinib, at low dosages, could not be entirely attributed to an induction of apoptosis, as assessed by 7-AAD staining as depicted exemplarily for native BCR/ABL and BCR/ABL-T315I (Figure 2d ).
PF-114 potently inhibits Ph+ patient-derived cell lines
To confirm the effects of PF-14 on human Ph+ patient-derived cell lines, we performed XTT assays on human Ph+ leukemia cell lines derived from ALL or CML patients. We used K562 and KCL-22 (both myeloid CML-BC expressing p210 BCR/ABL ) and the Ph+ lymphatic cell lines SupB15, Tom-1 (both Ph+ ALL expressing p185 BCR/ABL ) and BV-173 (lymphatic CML-BC expressing p210 BCR/ABL ). As a BCR/ABL negative control we used the Jurkat and Nalm-6 cells. Here we show that PF-114 inhibited proliferation of K562 and KCL-22 with an IC 50 of 8 and 9 nM, respectively. Jurkat and Nalm-6 cells were not affected in their growth (Figure 3a ). PF-114 inhibited proliferation of BV-173, Tom-1 (IC 50 of 5 nM) and SupB15 (IC 50 of 50 nM) cells (Figure 3b ).
Western blotting on lysates of SupB15 and K562 revealed a dose-dependent inhibition of autophosphorylation of BCR/ABL by PF-114 (Figure 3c injected subcutaneously into nude mice. Treatment was started at the moment the tumors reached a volume of about 500 mm 3 . PF-114 was administered at 25 and 40 mg/kg/day and ponatinib at 25 mg/kg/day. Tumor growth was completely inhibited by 40 mg PF-14 as compared with untreated mice within 10 days (Figure 4 ). At this dosage PF-114 caused a 100% reduction in mean tumor volume at the final measurement (P o 0.001) compared with the start of treatment and tumors did not recur even after 30 weeks from stopping the treatment (Figure 4) . In contrast at 25 mg/kg both PF-114 and ponatinib were able to cause a 100% reduction of the mean tumor volume within 4 and 2 weeks, respectively, but were unable to avoid recurrence of the tumor growth ( Figure 4 ). PF-114 suppresses growth of Ph+ PD-LTC with nonmutational resistance as well as T315I mutation Ph+ ALL in adults is not fully represented by cell lines. We took advantage of a recently established unique culture system for primary cells from Ph − and Ph+ ALL patients or lymphatic CML-BC patients, which remain genetically as well as immunophenotypically stable for at least 6 months, without entering senescence or passing the typical crisis of cell lines. Of 7 Ph+ PD-LTCs available, two expressed p210 BCR/ABL (VB and CM) and three p185 BCR/ABL (PH, DW and KW). 45, 53 Also the nonmutational TKIresistant BV and the T315I-positive KÖ PD-LTCs harbored the p185 BCR/ABL . To avoid the bias of unspecific toxicity of PF-114, the HP, a Ph − PD-LTC, was used as a negative control. Cytotoxicity/ proliferation was assessed by XTT. PF-114 inhibited the proliferation of all TKI-responsive PD-LTCs, with IC 50 values between 6 nM and a maximum of 20 nM and did not affect the proliferation of Ph − PD-LTC HP (Figure 5a ). The TKI-resistant BV and KÖ PD-LTC were inhibited by PF-114 at an IC 50 of 10 and 150 nM, respectively (Figure 5b) . The response of PD-LTCs toward PF-114 was related to the inhibition of BCR/ABL kinase activity as shown by the reduction of the BCR/ABL autophosphorylation in PH, BV and KÖ cells (Figure 5c ). PF-114 prolongs the survival of mice with both BCR/ABL-and BCR/ ABL-T315I-driven CML-like disease To evaluate the in vivo efficacy of PF-114 on native p185 BCR/ABL and p185-T315I BCR/ABL , we used a syngeneic mouse model for CML. 54 Sublethally irradiated C57BL/6N mice were transplanted with 10 5 Sca1 + BM cells expressing p185 BCR/ABL or p185-T315I BCR/ABL . The mice were treated with PF-114 (50 mg/kg) or ponatinib (25 mg/kg) once daily for 20 days. Both PF-114 and ponatinib extended median survival significantly from 28 days to 39 and 60 days, respectively (Figure 6a) .
In mice transplanted with p185-T315I BCR/ABL -expressing cells daily oral treatment with PF-114 and ponatinib for 20 days prolonged significantly median survival from 68 to 132 and 124 days, respectively (P = 0.006 for PF-114 and P = 0.04 for ponatinib) (Figure 6b ).
PF-114 prolongs the survival of mice with syngeneic BCR/ABLdriven ALL or harboring a xenograft of T315I-positive Ph+ ALL The BCR/ABL-driven CML-like disease in the mouse represents a model of CML-CP. To study the effect of PF-114 in an advanced Ph+ leukemia we took advantage from the fact that in our transduction/transplantation CML-like disease model in very rare cases (o 1%; data not shown) we obtained BCR/ABL-driven ALLs. These ALLs are dependent on BCR/ABL activity (data not shown). Thus, spleen cells from ALL mice were inoculated into sublethally (4.5 Gy) irradiated recipients. The mice were treated either with PF-114 (50 mg/kg) or ponatinib (25 mg/kg) for 20 days. PF-114 and ponatinib extended significantly the median survival from 31 to 41 and 46 days, respectively (Figure 6c) .
We recently established a PD-LTC (KÖ) from a Ph+ ALL patient harboring the T315I, 45, 55 which gives origin to a full blown leukemia in NSG mice within about 100 days. To investigate the efficacy of PF-114 in Ph+ ALL cells harboring the T315I we inoculated 4 × 10 6 KÖ into sublethally irradiated (2.5 Gy) NSG mice. Treatment for 14 days with either PF-114 (50 mg/kg) or ponatinib (25 mg/kg) significantly prolonged survival from a median of about 116 to 130 days (P = 0.0001) ( Figure 6d ) suggesting a clinical significance of PF-114 in advanced Ph+ leukemia even in the presence of T315I.
PF-114 selects a BCR/ABL-T315I-E255K compound mutation Clinically relevant mutations can be predicted by mutagenesis screens. Two methods are actually used: (i) the retrovirus-based screen that plays on the natural mutation rate of the reverse transcriptase during retroviral infection of Ba/F3 cells 37 or by pharmacologically induced point mutations using a mutagen, such as ethyl-nitrosurea. 26, 56 To confirm the resistance profile at the level of single mutations and to extend it to compound mutations, defined as two TKD mutations in the same molecule as a reason for resistance, 23, 26 we here used a modified reverse transcriptase mutagenesis screen as schematically described in Figure 7a . This method was used because mutations are limited to the provirus and do not involve the entire genome as in mutagentreated cells. At 50 nM, PF-114 suppressed all mutants with the exception of E255K or T315I or a combination of the two (Figure 7b ). The combination of T315I and T315L was about a clone with the integration of two provirus, one the original T315I and another mutated to T315L. At 100 nM, PF-114 suppressed all resistance mutants and allowed the outgrowth only of a combined T315I-E255K mutant (Figure 7b ). This mutant took origin from an additional mutation as confirmed by the fact that the triplet encoding the E255K did not correspond to the original cDNA sequence of the BCR/ABL-E255K clones (data not shown). At 500 nM, PF-114 suppressed all clones (data not shown). The resistance toward PF-114 was confirmed by the exposure of Ba/F3 retrovirally transduced with p185-T315I-E255K BCR/ABL to PF-114 and ponatinib (Figure 7c ).
DISCUSSION
In developing PF-114, we focused on three prerequisites for a novel ABL-targeting kinase inhibitor: (i) inhibition of native BCR/ ABL at nanomolar concentrations; (ii) potent inhibition of BCR/ ABL-T315I, and of other major TKD mutants; and (iii) the highest possible degree of selectivity in terms of inhibiting kinase targets. Utilizing the same scaffold as for imatinib, nilotinib and ponatinib, our structure-based chemical modifications ensured high-affinity binding to native BCR/ABL in the low nanomolar range with nearly the same potency as ponatinib. Furthermore no difference was seen between p210 BCR/ABL and p185 BCR/ABL , suggesting a similar degree of BCR/ABL kinase inhibition in CML and Ph+ ALL.
Although off-target effects of ABL-directed multikinase inhbitors have been credited with potential therapeutic value in CML, for example, the inhibition of SRC family kinases, they are also responsible for a variety of drug-related adverse events that compromise both short-term and long-term tolerability and safety, such as pleural effusions or pulmonary arterial hypertension by dasatinib, 18, 57 thrombocytopenia, arterial thrombosis rash, dry skin and abdominal pain by ponatinib 28 or liver function abnormalities and thrombocytopenia by INNO-406. 58 By direct comprehensive comparison of the kinase inhibition profiles of PF-114, nilotinib, dasatinib and ponatinib using the same biochemical assay, we demonstrate a significantly greater selectivity of PF-114, with fewer TKs inhibited by 490%. This was achieved by a rational molecular design of triazolopyridin moiety that preferably binds in the ATP-binding site of ABL compared with other kinases.
PF-114 is an orally available TKI, which is active in a range of 10-150 nM within it suppress all tested mutants. Its high tumorspecific activity was confirmed by the lack of any toxicity up to 5 μM in cellular assays using primary murine hematopoietic stem and progenitor cells, Ba/F3 cells, Ph − PD-LTCs and Ph − cell lines. Together with these data, the higher selectivity of PF-114 as compared with dasatinib and ponatinib suggests that PF-114 may Figure 7 . Compound mutations selected by PF-114. (a) Schematic representation of a modified reverse transcriptase-based mutagenesis screen. Ba/F3 cells infected with BCR/ABL and its indicated resistance mutants were selected to a 100% positive cell population for each construct by factor withdrawal. These populations were pooled in an exact proportional ratio and exposed to 50 and 100 nM (and 500 nM-not shown) of PF-114. PF-114 was freshly added with each medium change. After 28 days, the resulting bulk populations were subject to limiting dilution. Genomic DNA of resulting clones were then sequenced for the detection of primary mutations, as well as of additional compound mutations. (b) Resistant clones recovered from the pool of Ba/F3 cells infected with BCR/ABL and its mutants upon of PF-114 at 50 and 100 nM. Pre-existing mutations: outgrowth of clones from one of the mutant population in the pool (no changes in the sequence as compared with the provirus used for infection); new: additional mutations occurring in a provirus harboring one of the resistance mutations. (c) Resistance of the compound mutation BCR/ABL-T315I-E255K against PF-114 and ponatinib The effect of PF-114 on the factor-independent growth of Ba/F3 expressing BCR/ABL or BCR/ABL-T315I-E255K was performed on cells selected by IL-3 withdrawal. These cells were exposed to the indicated concentrations of PF-114 and ponatinib. Cell proliferation and viability was assessed by XTT assays.
have an improved risk profile as compared with these two compounds, which was confirmed on our toxicity studies in rats and dogs (see supplementary information). In particular, the lack of inhibition of members of the VEGFR-family might contribute to less cardiac or vascular toxicity, although the precise mechanisms of these adverse events have not yet been elucidated. In fact, also nilotinib presents an increased cardiovascular risk profile although unable to inhibit members of the VEGFR-family. 59 Even if our short-term toxicity studies in large animals suggest a good tolerance for PF-114, the risk profile of PF-114 has to be investigated in further toxicity studies and mainly in phase I studies. Regarding the potential selection of compound mutations in patients, PF-114, seems to select the E255 site in addition to T315I, similar to ponatinib. 26 Here we focused our experimental approach on the therapeutic potential of PF-114 for Ph+ lymphoid leukemias using in vitro and in vivo models that closely represent human Ph+ ALL, as this type of leukemia is clinically particularly aggressive and susceptible to clonal evolution. In the PD-LTCs, PF-114 was highly effective not only for cells harboring the BCR/ABL-T315I, but also for patientderived samples displaying nonmutational resistance. Even though the resistance mechanisms in these cells are not known, these data further strengthen the rationale for use of PF-114 as treatment for advanced, therapy-refractory Ph+ leukemia.
Our pharmacokinetic studies, together ( Supplementary Table S3 ) with the excellent response in our xenograft models of high-risk Ph+ ALL in NSG mice, with and without BCR/ABL-T315I, clearly show that PF-114 has sufficient oral availability as to exert a potent antileukemic effect not restricted to CML-CP, but also on aggressive human Ph+ ALL.
The F317L mutation that is implicated in clinical resistance to dasatinib 21, 23, 60 was the only mutation for which our cellular assays showed an IC 50 beyond the 10-100 nM range, at 150 nM, and in direct comparison was less potent than ponatinib. This concentration of 150 nM is likely to be clinically achievable based on our toxicity data, making it likely that PF-114 will have clinical efficacy even in patients with BCR/ABL-F317L as also confirmed by its inhibition of ABL-F317I in the cell-free kinase assay and by the fact that in the resistance screen no BCR/ABL-F317L-positive clone was detected.
In conclusion, PF-114 is a highly potent, yet selective, TKI in biochemical cellular and in vivo assays with a very good toxicity profile, suggesting significant therapeutic potential in CML and high-risk advanced Ph+ leukemia. Its ability to overcome TKI resistance induced by either BCR/ABL-T315I or other major resistance mutations, or mutation-independent mechanisms makes PF-114 a promising candidate for the treatment of CML and Ph+ ALL patients resistant or refractory to all currently available TKIs.
